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ThymusThymic atrophy occurs during normal aging, and is accelerated by exposure to chronic stressors that
elevate glucocorticoid levels and impair the naïve T cell output. The orexigenic hormone ghrelin was
recently shown to attenuate age-associated thymic atrophy. Here, we report that ghrelin enhances
the proliferation of murine CD4+ primary T cells and a CD4+ T-cell line. Ghrelin induced activation of
the ERK1/2 and Akt signaling pathways, via upstream activation of phosphatidylinositol-3-kinase
and protein kinase C, to enhance T-cell proliferation. Moreover, ghrelin induced expression of the
cell cycle proteins cyclin D1, cyclin E, cyclin-dependent kinase 2 (CDK2) and retinoblastoma phos-
phorylation. Finally, ghrelin activated the above-mentioned signaling pathways and stimulated thy-
mocyte proliferation in young and older mice in vivo.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
The thymus is required for the generation of T cells, a develop-
mental process that is maintained throughout adolescence and
early adulthood, and then progressively declines with advancing
age [1,2]. The thymus and developing thymocytes are highly sensi-
tive to both physiological and pathological stressors, such as infec-
tions, immunosuppressive treatments, surgery, anxiety/depression
and malnutrition, which can result in the apoptosis of developing
thymocytes [3–7]. Such stressors result in increased production
of glucocorticoids (GCs) [8–10]. Excessive production of GCs as a
result of hypothalamus–pituitary–adrenal (HPA) axis hyperactiva-
tion also occurs in inﬂammatory conditions and aging [5,11]. GCshave been established as major regulators of thymocyte and
mature lymphocyte apoptosis [4,8,9]. The synthetic GC, dexameth-
asone, is routinely used to suppress immune functions in organ
and bone marrow transplant recipients, in autoimmune and sys-
temic inﬂammatory disorders and in the treatment of malignancies
[13]. Adverse effects of these GCs on thymic activity and integrity
have been established and the underlying alterations of T cell sig-
naling pathways that regulate cell activation and proliferation are
being elucidated [5,11,12].
Several hormones and cytokines are involved in GC-mediated
thymic atrophy, and seem to inﬂuence thymocyte survival, prolif-
eration and gene expression [4,13]. Here, we focused on the hor-
mone ghrelin — an acylated 28-amino-acid polypeptide that is
secreted by the X/A-like enteroendocrine cells of the stomach
and plays a major role in the regulation of food intake, adiposity
and energy homeostasis [13,14]. Activated ghrelin has an n-octa-
noyl group covalently linked to the hydroxyl group of the serine
3 (Ser3) residue, which is critical for its binding to the G-protein
coupled growth hormone secretagogue receptor-1a (GHS-R1a)
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pituitary gland induces GH release through enhanced phospholi-
pase C (PLC) and protein kinase C (PKC) activation and intracellular
calciummobilization [16]. Moreover, ghrelin mediates diverse bio-
logic functions beyond its effects on the central nervous system
[17]. It increases cell proliferation, and inhibits apoptosis of cardio-
myocytes, endothelial cells and enterocytes [18], and it is expected
that additional functions of this potent hormone will be identiﬁed
in the near future, given the wide distribution of GHS-Rs in a vari-
ety of tissues and cell types [18,19].
GHS-R1a-mediated mobilization of calcium is one of the best
characterized intracellular events resulting from GHS-R1a activa-
tion [20]. Growth hormone (GH) secretagogues stimulate intracel-
lular calcium mobilization mediated via the activation of PLC
through the GTP-binding protein (Gaq11) [21]. PLC cleaves the
membrane lipid phosphatidylinositol 4,5 diphosphate (PIP2) into
diacylglycerol (DAG) and inositol (1,4,5) triphosphate (IP3). IP3 rep-
resents one arm of this cascade andmediates the release of calcium
from the endoplasmic reticulum. DAG activates PKC, which in turn
phosphorylates multiple protein substrates resulting in speciﬁc
phenotypic responses of the cells [22]. The pro-proliferative activ-
ity of ghrelin may involve the activation of the downstream mito-
gen-activated protein kinases (MAPK) and Akt (also known as
protein kinase B) in several cell types [19,23,24]. In Chinese ham-
ster ovary cells engineered to overexpress GHS-R1a, ghrelin
administration activated ERK1/2 via a PLC- and PKCe-dependent
pathway [21]. Similarly, the mitogenic effect of ghrelin on endo-
thelial cells and 3T3-L1 preadipocytes is mediated by the PI3K/
Akt and MAPK pathways [25,26].
Recent studies have demonstrated a potential role for ghrelin in
inﬂuencing the immune system and inﬂammatory responses
[1,3,19,27,28]. Ghrelin receptors are present in several leukocyte
subsets, and immune cells (such as T cells, monocytes, dendritic
cells) can also produce ghrelin [3,5]. Moreover, exogenous admin-
istration of ghrelin can ameliorate both acute and chronic inﬂam-
matory conditions [3]. However, little is known about the effect
of GHS-R1a activation on signal transduction pathways in immune
cells, in general, and on the proliferation and activation of T cells, in
particular.
Here, we report that ghrelin partially reverses dexamethasone-
induced thymocyte ablation and increases thymocyte cell prolifer-
ation in vivo. Analysis of the signaling pathways associated with
the proliferative effects of ghrelin revealed that GHSR-1a ligation
results in the activation of the PI3-kinase, PLC, Akt and MAP kinase
signaling pathways in both primary murine CD4+ T cells and mur-
ine CD4+ T hybridoma cells stably expressing the GHS-R1a recep-
tor. Ghrelin-mediated activation of these pathways results in an
enhancement of T-cell proliferation and activation, inﬂuences cell
cycle progression upon TCR ligation, and enhances recovery from
glucocorticoid-mediated thymic atrophy. These ﬁndings advance
our understanding of the mechanisms through which ghrelin pro-
tects against thymic involution, with implications for aging,
chronic stress and associated diseases.2. Materials and methods
2.1. Reagents
All supplements for cell culture were obtained from Invitrogen
(Carlsbad, CA). Recombinant rat ghrelin (acylated ghrelin) was pur-
chased from GenScript (Piscataway, NJ), and rat des-octanoyl ghre-
lin was from Tocris Bioscience (Ellisville, MO). The PI3-kinase
inhibitor Wortmannin, the ERK inhibitor PD98059, the p38 inhibi-
tor SB203580, the JNK inhibitor SP600125 and the PLC inhibitor
U73122 were obtained from EMD Chemicals (Gibbstown, NJ).Antibodies against phosphorylated forms of Akt (D9E), ERK1/2
(E10), p38, JNK, Cyclin D (92G2), Rb and the various PKC family
members were purchased from Cell Signaling Technology (Beverly,
MA). The GHS-R1a antibody for immunostaining was obtained
from Phoenix Pharmaceuticals, Inc. (Burlingame, CA). Alexa-Fluor
488-conjugated goat anti-rabbit antibody was purchased from
Invitrogen. The antibodies speciﬁc for GHS-R1a (H-80), Cyclin E
(E-4), CDK2 (D-12), CDK4 (C-22) and actin (I-19) used for Western
blotting were purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). Stripping buffer for membrane reprobing was obtained
from Thermo Fisher Scientiﬁc Inc. (Waltham, MA). Pertussis toxin
was purchased from Sigma–Aldrich (St. Louis, MO). The MTS assay
kit for cell proliferation was purchased from Promega (Leiden, the
Netherlands).
2.2. Animals and experimental protocol
C57BL/6 male mice (8–10 weeks old) were purchased from The
Jackson Laboratories (Bar Harbor, ME) and experiments were per-
formed under a protocol approved by the National Institute on
Aging Animal Care and Use Committee. The mice were maintained
under a 12 h light and 12 h dark cycle. Mice were injected i.p. with
100 lg/kg ghrelin or des-acyl ghrelin or 0.9% saline (control) every
12-h for 1 or 3 days. In some aged mouse experiments, mice were
infused with PBS or ghrelin using osmotic minipumps as previ-
ously described [1]. In the BrdU incorporation studies, 2 h prior
to euthanasia the treated mice were injected i.p. with 100 mg/kg
BrdU (Sigma). The thymus was subsequently isolated and cut in
half for immunohistological examination. Half of the thymus was
ﬁxed in 10% neutral buffered formalin and parafﬁn-embedded.
Deparafﬁnized sections (5–10 lm) were stained with diam-
inobenzidine (Vector Laboratories, Burlingame, CA) and analyzed
by light microscopy. As a negative control for the primary T cell
proliferation studies, CD4+ T cells derived from GHS-R null mice
(generously donated by Dr. Roy Smith, The Scripps Research Insti-
tute, Jupiter, FL) were utilized as described previously [1,27,28].
2.3. Primary T cell preparation
Eight week-old mice were euthanized and single-cell suspen-
sions were made of the spleen or thymuses in cold Hank’s balanced
saline solution (HBSS) with 1% fetal bovine serum (FBS) (Invitro-
gen). After the removal of contaminating red blood cells using
ACK lysis buffer (Quality Biological, Inc., Gaithersburg, MD), CD4+
T cells were isolated using the mouse CD3+ CD4+ T-cell enrichment
column (R&D System, Minneapolis, MN) or using mouse CD4+ T
cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany)
and kept in RPMI supplemented with 10% FBS (Invitrogen) and
50 lM b-ME under 5% CO2 at 37 C.
2.4. GHS-R1a-transfected CD4+ T-cell hybridoma line
A GHS-R1a transfected CD4+ T cell line called D0.11.10 was gen-
erated and utilized for the majority of cell signaling analyses exam-
ined in this study. Total RNA was isolated from the murine
pituitary gland and cDNA was prepared using SuperScript III
ﬁrst-Strand Synthesis System for RT-PCR and ampliﬁed by PCR
using Bam HI overhang primers as described previously [29].
PCR-products were directly cloned into pcDNA3.1/V5-His TOPO
TA vector, which was subsequently and stably transfected in the
CD4+ T-helper cell hybridoma line, D0.11.10. These transfected
cells were selected for and grown in G418 (Calbiochem)-supple-
mented medium containing RPMI 1640 with 10% FBS, 1% penicil-
lin/streptomycin, 4% HEPES and 1% sodium pyruvate in a
humidiﬁed atmosphere of 5% CO2/95% room air. These lines were
subsequently subcloned and individual transfected clones were
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ing GHS-R1a were isolated and utilized in these studies (Fig. 1).
2.5. Confocal microscopy
D0.11.10 cells (1  105) were placed on slides using a cytospin
centrifuge (Thermo Fisher Scientiﬁc, Asheville, NC) for 3 min at
800 rpm after which the cells were ﬁxed with 4% formaldehyde
in PBS for 20 min. The slides were subsequently blocked with
0.5% bovine serum albumin for 1 h and then stained with rabbit
anti-GHS-R1a antibody overnight at 4 C. After incubation, the cells
were subsequently incubated with Alexa-Fluor 488-conjugated
goat-anti-rabbit antibody and the recombinant cholera toxin sub-
unit B-conjugated Alexa Fluor 594 for 1 h. After washing the
slides three times with PBS, the ProLong Gold anti-fade reagent
(Invitrogen) was added to the slides, which were then coverslipped
and dried overnight at room temperature. Fluorescence micros-
copy was performed using a Carl Zeiss LSM 510 confocal micro-
scope (Oberkochen, Germany). Alexa-Fluor-488 and Alexa-Fluor-
594 were excited with an Ar (488 nm) or He-Ne (543 nm) laser
and emission was ﬁltered using narrow band LB 505–530 nm
and the LP 560 nm ﬁlters, respectively. Images were then analyzed
using Carl Zeiss LSM image software 3.0.0
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Fig. 1. Acylated ghrelin administration induces thymocyte subset proliferation in
dexamethasone-treated mice. C57BL/6 mice were injected with acylated ghrelin at
100 lg/kg over a 24 h time period in the presence or absence of dexamethasone
after which the thymocytes were examined for thymocyte subset numbers and the
number of BrdU-positive subset cells using ﬂow cytometric analysis as described in
the Methods. Each group included 5 mice. The data are expressed as either (A) the
absolute thymocyte subset numbers (106 cells), or (B) BrdU-positive cells (106
cells). Values represent the mean and S.E.M. of determinations made in three
independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01.2.6. Cell proliferation assay
Cells were plated (3.0  103 cells per well) in 96-well plates and
stimulated with recombinant ghrelin or des-acylated ghrelin for
speciﬁed time periods at 37 C in a humidiﬁed, 5% CO2 atmosphere.
After incubation, 20 ll of MTS reagent (CellTiter 96 Aqueous one
solution cell proliferation assay, Promega) was added to the cul-
tures. After 1 h incubation, the intensity of the absorbance was
quantiﬁed using an ELISA microplate reader at an absorbance of
592 nm. The data are expressed as % proliferation (±S.E.M.).
2.7. Immunoblot analysis
Protein lysates were prepared from T cells by lysing them in
RIPA buffer containing a protease inhibitor cocktail tablet (Roche)
and phosphatase inhibitors (Sigma), and then incubated on ice
for 10 min, followed by centrifugation at 15000g for 15 min at
4 C. Protein concentrations were subsequently determined and
30 lg of each sample were separated using SDS–PAGE and then
transferred onto PVDF membranes. The membranes were subse-
quently blocked in a TBS-T buffer (10 mmol/L Tris–HCl [pH 7.5],
150 mmol/L NaCl, and 0.05% Tween 20) containing 5% skimmed
milk powder for 1 h, after which the membrane was incubated
with individual primary antibodies at 4 C overnight. After washing
with a TBS-T buffer, the membrane was then incubated with horse-
radish peroxidase-coupled secondary antibodies for 1 h at room
temperature. Blotting detection was subsequently conducted using
an enhanced ECL detection system (Amersham Biosciences, Buck-
inghamshire, UK).
2.8. Cell cycle analysis by propidium iodide (PI) staining
T cells were plated at 1  106 cells per well in 12-well plate for
16 h at 37 C. After treatment with 10 nM ghrelin, the cells were
incubated for the designated time periods, and then washed twice
and suspended into 70% ethanol for 30 min at 4 C. Cells were sub-
sequently washed once, and suspended in 500 ll of PI solution
(25 lg/ml PI, 0.1 mg/ml of RNase A in PBS) and then incubated
for 30 min in darkness. The cells were analyzed by ﬂow cytometric
analysis using a FACScan (Becton Dickinson, San Jose, CA), followed
by data analysis using MultiCycle (Phoenix Flow Systems, San
Diego, CA).
2.9. Real-time PCR analysis
One half to one microgram of RNA was puriﬁed and quantitated
from each sample and made into cDNA with the iScript cDNA syn-
thesis kit (BioRad, Hercules, CA). One microliter of each cDNA sam-
ple was then used to measure quantity using the SYBR Green PCR
master mix (Applied Biosystems) and reactions were run on the
7500 fast or 7300 PCR system (Applied Biosystems). The results
were normalized to 18S using the QuantumRNA universal 18S
(Ambion, Austin, TX) and were also used to determine relative
quantities. The GHS-R primers utilized in this study were described
previously [30].2.10. PKC activity assay
In order to determine the effect of ghrelin on PKC activity, we
measured PKC activity in cell lysates. Samples were prepared from
T cells by lysing them in RIPA buffer after which the lysates were
centrifuged at 15000g for 15 min at 4 C. These supernatants
were assayed using the PKC Kinase Activity Assay Kit (EKS-420A;
Stressgen Bioreagents, Victoria, BC, Canada). Samples were assayed
in triplicate.
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The data are presented as the mean ± S.E.M. from three or more
independent experiments. All statistical signiﬁcance was deter-
mined by ANOVA using the Statistical Analysis System (SAS, Cary,
NC). Comparisons between two groups were performed using Stu-
dent’s t-test. Pairwise comparisons for data with multiple time
points or treatment concentrations were done using Duncan’s mul-
tiple range test. A value of P < 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Ghrelin induces thymocyte proliferation in dexamethasone-
treated mice
Dexamethasone (Dex), a potent synthetic member of the gluco-
corticoid class of steroid drugs can mimic the effects of endoge-
nous GCs by inducing thymic ablation through the programmed
cell death of thymocytes, and in particular of the immature dou-
ble-positive (DP) subset [2,31]. We ﬁrst examined the ability of
ghrelin infusion to promote a restoration of thymocyte numbers
and proliferation after Dex treatment. Thymocyte proliferation
was increased already at day 1 following combined Dex and ghre-
lin treatment as compared to Dex treatment alone (Fig. 1B). Ghre-
lin also increased the absolute numbers of DP thymocytes in the
Dex-treated mice (Fig. 1A). Ghrelin and the saline vehicle control
failed to induce signiﬁcant changes in cell numbers and prolifera-
tion when administered to mice that had not received any DexFig. 2. Expression of GHS-R1a in the murine CD4+ T cells and a CD4+ GHSR1a-transfecte
control vector alone or the vector containing the GHS-R1a gene were processed for analys
by immunoblot analysis (B). Values represent the mean and S.E.M. of determinations ma
cells. (C) The transfected cells were examined for responsiveness to ghrelin through the
D0.11.10 cells were stimulated with 10 nM ghrelin for 7 min after which cell lysates wer
the representative results are shown. The numbers under each blot are intensity of the ER
of GHS-R1a, the GHS-R-transfected D0.11.10 cells (1  105) were co-stained using rabbi
subunit B (green) which binds selectively to the membrane lipid raft marker ganglioside
Cells (3  103) were treated 10 nM ghrelin or vehicle in 96-well plates for various time in
are expressed as % cell proliferation and values represent the mean and S.E.M. of determin
##P < 0.05, P < 0.01 compared to the pcDNA value at the same time point. P < 0.01 cotreatment. These in vivo data suggest that ghrelin promotes thy-
mocyte proliferation and survival [1].
3.2. Ghrelin-induced proliferation of T cells is both Akt- and Erk1/2-
dependent
To examine the signaling pathways that act downstream of
GHS-R1a in T cells, we transfected the murine D0.11.10 CD4+ T cell
line with GHS-R1a. GHS-R1a mRNA expression was 140-fold
higher in GHS-R1a-transfected D0.11.10 CD4+ T cells than in con-
trol pcDNA-transfected cells, following normalization for 18S
expression (Fig. 2A). This increased receptor expression corre-
sponded to higher GHS-R1a protein levels (Fig. 2B). Moreover,
GHS-R1a was found to be biologically active in D0.11.10 CD4+ T
cells, as treatment with ghrelin resulted in a signiﬁcant increase
in phospho-ERK levels in GHS-R1a-transfected but not in pcDNA-
transfected cells (Fig. 2C). Previous studies from our laboratory
demonstrated that GHS-R1a localizes within lipid rafts upon T cell
activation and that this association might be necessary for optimal
GHS-R1a activity [28]. In our examination of the D0.11.10 transfec-
tants under laser confocal microscopy, we found that the GHS-R1a
receptor was expressed constitutively on the surface of the GHS-
R1a transfected cells and localized within the ganglioside GM1
lipid raft domain (Fig. 2D).
Given previous ﬁndings demonstrating the proliferative effects
of ghrelin in tumor cells and several types of normal cells
[3,19,23,24], we next examined the effects of ghrelin on the
proliferative response of GHS-R1a-transfected D0.11.10 cells.
GHS-R1a-transfected D0.11.10 cells stimulated with ghrelind T cell hybridoma line, D0.11.10. D0.11.10 cells transfected with either the pcDNA
is of either GHS-R1a mRNA levels by real time RT-PCR (A) or GHS-R1a protein levels
de in three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared to control (EL4)
examination of phosphorylated ERK levels. The pcDNA- and GHS-R1a-transfected
e examined by immunoblot for pERK levels. Experiments were repeated 3 times and
K band relative to that of the b-actin band. (D) To assess the cell surface expression
t anti-GHS-R1a antibody (red) and ﬂuorescently tagged recombinant cholera toxin
GM1. Areas of co-localization are indicated by yellow color in the overlay image. (E)
tervals after which cell proliferation was examined using the MTS method. The data
ations made in four independent experiments. ⁄P < 0.05 ⁄⁄P < 0.01, compared to 0 h;
mpared to the values of each of the other groups at the same time point.
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treated cells and the pcDNA-transfected D0.11.10 cells (Fig. 2E).
The ghrelin-mediated effects on cell proliferation were GHSR-1a-
speciﬁc, as the GHSR-1a selective antagonist, D-Lys-GHRP-6, sig-
niﬁcantly inhibited the ghrelin-mediated pro-proliferative effects
on D0.11.10 cells (data not shown). These data suggested that
these transfected cell lines would be valuable in examining the sig-
naling effects of ghrelin on murine T cells and potential roles for
ghrelin in T cell proliferative and activation responses.
The ERK and Akt signaling pathways are known to play impor-
tant roles in cellular proliferation [32]. To evaluate the role of the
Akt, Erk1/2 and PI-3-kinase signaling pathway(s) on ghrelin activa-
tion of murine T cells, a kinetic analysis was performed examining
the ability of ghrelin (10 nM) to stimulate GHS-R1-transfected
D0.11.10 cells for various time periods (Fig. 3A). Ghrelin induced
Akt and ERK 1/2 phosphorylation within 30 s after stimulation
and this activity was sustained for 15–30 min, with maximal
increases in levels of both phosphorylated kinases being observed
at 3 min. Ghrelin also induced phosphorylation of c-Jun N-terminal
kinase 1/2 (JNK1/2) and p38, both of which are known to play a
role in cellular activation and proliferation of lymphocytes [33].
A dose–response analysis was then performed with ghrelin con-
centrations ranging between 1 and 10 nM, and maximum Akt
and ERK activation was shown to occur 7 min after treatment with
the highest ghrelin concentration (Fig. 3B). Thus, a ghrelin concen-
tration of 10 nMwas used in the majority of the subsequent exper-
iments in this study.
The pro-proliferative effect of ghrelin on GHS-R1a- transfected
D0.11.10 T cells was signiﬁcantly inhibited by the PI3-kinase inhib-
itor wortmannin, as well as by the ERK1/2 inhibitor PD98059
(Fig. 4A). These results suggested that ghrelin stimulates T cell pro-
liferation in a PI3-kinase-, Akt- and Erk-dependent manner. This is
supported by the data in Fig. 4B, which show that wortmannin
inhibits ghrelin-induced Akt phosphorylation and ERK activation
in a concentration-dependent manner. Thus, the ability of ghrelin
to activate both Akt and ERK1/2 is highly dependent on PI3-kinase
activity. Wortmannin treatment at concentrations as low as
0.03 lM almost completely abrogated ghrelin-induced phosphory-
lation of Akt and ERK1/2. None of the concentrations of wortman-
nin applied in these studies were found to be toxic, and no
inhibitory responses were observed using vehicle alone (data not
shown). Interestingly, GHS-R1a-transfected D0.11.10 T cells that
had been pre-treated with various doses of PD98059 (a MEK1
inhibitor that has been shown to act as a highly selective inhibitor
of MEK1 activation and the MAP kinase cascade) revealed that onlyFig. 3. Kinetic and dose response analysis of the effects of ghrelin on Akt and ERK1/2 pho
incubated for the indicated time periods with ghrelin at 10 nM (A) or with increasing co
proteins were examined by immunoblot analysis using antibodies speciﬁc for phosphoryl
and representative blots are shown. The density of each band was measured by Multi G
b-actin band for the same sample.ghrelin-mediated ERK1/2, but not Akt, phosphorylation was inﬂu-
enced by MEK1 inhibition, suggesting that ghrelin-induced Akt
phosphorylation was independent of ERK1/2 activation (Fig. 4B).
The addition of SB203580, a potent inhibitor of the p38-MAP
kinase pathway, had no signiﬁcant inhibitory effects on ghrelin-
induced T cell proliferation. However, it should be pointed out that
the addition of SB203580 alone enhanced cell proliferation making
data interpretation difﬁcult. Moreover, the addition of SP600125, a
selective inhibitor of JNK1/2, resulted in signiﬁcant albeit modest
effects on ghrelin-induced T cell proliferation (Fig. 4A). These data
suggest that although ghrelin stimulates the phosphorylation of
JNK1/2 and p38 in GHS-R1a-transfected D0.11.10 cells, these
kinases may not play a major role in ghrelin-mediated proliferation
in GHS-R1a- transfected D0.11.10 T cells.
3.3. The GHS-R mediated Akt and Erk1/2 activation requires PLC, but
not PTX-sensitive G proteins
GHS-R1a is a G-protein coupled receptor, and ghrelin has previ-
ously been shown to activate ERK1/2 through a Ga(i)-dependent
pathway in several cell types [34,35]. In an effort to determine if
G-protein signals associated with GHS-R1a mediated ghrelin-
induced proliferation of T cells, we pretreated the cells for 24 h
with pertussis toxin (PTX, 100 ng/ml), which inactivates the het-
erotrimeric G-proteins coupled to the GPCRs, and then subse-
quently examined its effects on ghrelin-mediated T-cell
proliferation. The results in Fig. 5A reveal that pre-treatment with
pertussis toxin failed to inhibit ghrelin-induced proliferation at 24
or 48 h. This is further supported by the lack of any effect of pertus-
sis toxin addition on ghrelin-mediated Akt and ERK1/2 phosphory-
lation (Fig. 5B). In contrast, U73122 (1 lM), an inhibitor of
phospholipase C (PLC)-dependent processes, suppressed both
ghrelin-induced cell proliferation (at 24 h and 48 h) and Akt and
ERK1/2 phosphorylation in a concentration-dependent manner
(Fig. 5A and B). As Gaq is known to activate PLC [23], these results
suggest that ghrelin increases cell proliferation via a Gaq- and PLC-
dependent pathway.
The activation of PLC stimulates the conversion of PIP2 to IP3
and DAG, resulting in the release Ca2+ from intracellular stores
and activation of PKC, respectively. To determine if the effects of
ghrelin on Akt and Erk1/2 phosphorylation depends on the release
of intracellular calcium, T cells were treated with the Ca2+ chelator,
BAPTA-AM (10 lM), and the effects of ghrelin on Akt, ERK 1/2 and
PKC activation were determined (Fig. 5C). Similarly with the
inhibitory effects of wortmannin (Fig. 3), treatment of T cells withsphorylation in D0.11.10 cells. D0.11.10 GHS-R1a-transfected T cells (2  106) were
ncentrations of ghrelin for 7 min (B), after which the cells were lysed and extracted
ated residues of Akt, ERK1/2, JNK1/2 and P38. Experiments were repeated 4–5 times
auge V3.1 software (Fujiﬁlm, Tokyo, Japan) and normalized to the intensity of the
Fig. 4. Ghrelin enhances D0.11.10 cell proliferation and activation via PI-3-kinase, Akt and ERK1/2 pathways. (A) D0.11.10 cells (3  103) were pretreated with wortmannin
(0.3 lM), PD98059 (10 lM), SB203580 (10 lM) or SP600125 (10 lM) or 0.1% DMSO vehicle control (CTR) for 30 min prior to treatment with 10 nM ghrelin. After incubation
for 24 or 48 h, the plates were examined for cell proliferation using MTS assay. The data are expressed as the percentage of cell number compared to the CTR group at time 0.
Values represent the mean and S.E.M. of determinations made in three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared to 0 h (control); #P < 0.05, ##P < 0.01
compared to ghrelin treatment. (B) D0.11.10 cells (2  106) were cultured with 10 nM ghrelin in the presence or absence of various concentrations of wortmannin or PD98059
for 30 min after which the cells were lysed and examined for Akt and ERK1/2 phosphorylation via immunoblot analysis. These blots are representative of results obtained in 5
separate experiments.
Fig. 5. Evidence that the effects of ghrelin on T cell proliferation and Akt and ERK1/2 phosphorylation are mediated by PLC. D0.11.10 cells (3  103) were incubated in the
presence or absence of ghrelin (10 nM) for the indicated time periods with pertussis toxin (PTX; 100 ng/ml), U73122 (1 lM), BAPTA-AM or vehicle alone. (A) Cell proliferation
was examined at 24 and 48 h as determined by the MTS assay. The data are expressed as % cell proliferation, and the values represent the mean and S.E.M. of determinations
made in three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared to 0 h (control); #P < 0.05, ##P < 0.01 compared to ghrelin treatment. (B) GHS-R1a-transfected
D0.11.10 cells (2  106) were incubated with different concentrations of PTX or U73122 in the presence or absence of ghrelin at 10 nM for 7 min after which the cultures were
lysed and examined by immunoblot analysis using antibodies speciﬁc for phospho-Akt and ERK1/2. (C) Cells were pre-incubated with 0, 3, 10 and 30 lM BAPTA-AM for 1 h
prior to ghrelin treatment for 7 min, at which time cells were harvested and processed for immunoblot analysis. Experiments were repeated 4–5 times and representative
blots are shown. The numbers under each blot are the intensity of the indicated band relative to that of the b-actin band.
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phosphorylation (Fig. 5C), as well as PKC activation, suggesting that
ghrelin-induced activation of T cells involves the release of intra-
cellular Ca2+ and the activation of PKC.3.4. PKCc and PKCf are speciﬁcally activated by ghrelin
Previous reports have demonstrated that ligation of GHS-R1a
with ghrelin or receptor-speciﬁc agonists results in an increase in
4714 J.H. Lee et al. / FEBS Letters 588 (2014) 4708–4719intracellular Ca2+ levels, following Ca2+ release from IP3-sensitive
stores [36]. This Ca2+ release subsequently leads to the activation
of various PKC isoforms. Using a pan anti-phosphorylated PKC anti-
body, we observed that ghrelin indeed induces PKC phosphoryla-
tion in GHS-R1a- transfected D0.11.10 T cells cells (Fig. 5C). The
PKC isoforms PKCc and PKCf were speciﬁcally phosphorylated
upon treatment of GHS-R1a- transfected D0.11.10 T cells with acyl-
ated ghrelin (Fig. 6A and B). Little or no effect of ghrelin was
observed for the PKC isoforms a, b, l, d, or h (Fig. 6A). As expected,
stimulation of the cells with the phorbol ester PMA resulted in the
phosphorylation of many of the PKC isoforms. Moreover, the data
shown in Fig. 6B also reveal that the kinetics of ghrelin-induced
phosphorylation of PKCc and PKCf are similar to the kinetics of
ghrelin-induced Akt and ERK1/2 phosphorylation.
To determine if PKC activation is involved in the ghrelin-
induced activation of Akt and ERK1/2, we treated the GHS-R1a-
transfected D0.11.10 T cells with the PKC inhibitors Gö6983
(10 lM) and GF109203X (2 lM). Gö6983 inhibits PKCa, PKCb,
PKCc, PKCd and PKCf, whereas GF109203X inhibits PKCa, PKCb,
PKCc, PKCd and PKCe. We found that phosphorylation of both
phospho-Akt and –ERK1/2 was inhibited using either of the PKC
inhibitors (Fig. 6C and D). Together, these results suggest that ghre-A
C
Fig. 6. Ghrelin induces the activation of the PKC isoforms PKCc and PKCn, which are re
transfected cells (2  106) were treated with ghrelin (10 nM) for the indicated time period
of the phosphorylated PKC isoforms. Phorbol 12-myristate 13-acetate (PMA, 50 ng/ml) w
forms of PKC. Actin levels were included to demonstrate that equivalent quantities of pr
inhibitors for 30 min after which the cells were treated with ghrelin (10 nM) or 50 ng/m
phosphorylation were examined. Experiments were repeated 5 times and representative
relative to that of the b-actin band. (D) PKC activity of the particulate fraction was measur
in Materials and Methods. The values are the mean and S.E.M. for three independent exlin-induced T-cell proliferation and the activation of Akt and ERK1/
2 is associated with the activation of PKCc and PKCf.
3.5. Ghrelin promotes expression of cell cycle proteins
When cells enter the cycle from G0, Cyclin D1 is a key protein
involved in phosphorylation and consequent inactivation of the
cell cycle inhibitor retinoblastoma protein (Rb) [37]. Both of these
cell cycle regulatory proteins are regulated by the ERK1/2 and Akt
signaling pathways [38]. Based on our cell proliferation and protein
phosphorylation ﬁndings, we examined the effects of ghrelin on
the expression of cell-cycle regulatory proteins at various times
after ghrelin treatment. Total cyclin D1 protein levels were signif-
icantly increased by ghrelin, with signiﬁcant effects being observed
2 h post treatment and maximal levels at 48 h, corresponding to
the optimal time period for ghrelin-induced proliferation in GHS-
R1a- transfected D0.11.10 T cells (Fig. 7A). Similar increases in
ghrelin-induced protein expression were observed for cyclin E
(between 2 and 24 h) and CDK2 (between 24 and 48 h). In addition,
ghrelin also induced the phosphorylation of Rb at S807/811, but
not at S780, within 1 h (Fig. 7A). No signiﬁcant effects were
observed on CDK4 expression in response to ghrelin treatment.B
D
quired for ghrelin-induced activation of Akt and ERK1/2. (A, B) D0.11.10 GHS-R1a-
s after which the cells were lysed and examined byWestern blot analysis for several
as utilized in these studies as a positive control as it is capable of activating several
otein were loaded in each lane. (C) D0.11.10 cells were pretreated with various PKC
l of PMA for 7 min. After incubation, cell lysates were prepared and Akt and ERK1/2
blots are shown. The numbers under each blot are the intensity of the indicated band
ed using the Assay Designs non-radioactive PKC activity ELISA assay kit as described
periments. ⁄P < 0.05, ⁄⁄P < 0.01 compared to PBS control. #P < 0.05, ##P < 0.01.
B 
Cyclin D1 
Cyclin E 
CDK2
CDK4
Actin 
Rb
pS780-Rb
pS807/811-Rb
0          1          2        6        12        24       48  hr 
Density     1.0        1.1       1.9        2.9       3.1       4.2        5.0 
Density     1.0        0.9       0.8        0.9       0.9        0.8      1.0 
Density     1.0        2.5       2.6       2.6       2.7        2.2       2.3 
Density      1.0       1.0       0.9       1.0       1.1       1.0       1.0 
Density     1.0         1.1      1.0       0.9        0.8       1.0       0.8 
Density     1.0        3.6     10.2      14.4     11.6      1.9        1.2 
Density     1.0        1.3      1.0       1.0        1.2       1.5        2.0 
10 nM Ghrelin 
*
20
60
30
40
50
70
80
G1               S             G2/M   
CTR 
GRL *
PI
 p
os
iti
ve
 c
el
ls
 (%
) 
A 
Fig. 7. Analysis of ghrelin-induced expression of cell-cycle proteins and entry in D0.11.10 cells expressing GHS-R1a. (A) D0.11.10 cells (2  106) were treated with ghrelin
(10 nM) for various time intervals after which cell lysates were prepared and subsequently examined by immunoblot analysis using antibodies speciﬁc for the
phosphorylated forms of Rb or the total proteins for cyclin D1, cyclin E, CDK 2 and CDK4. Experiments were repeated 4 times and representative blots are shown. The numbers
under each blot are the intensity of the indicated band relative to that of the b-actin band. (B) D0.11.10 cells (1  106) were treated with ghrelin (10 nM) for 12 h after which
the cells were ﬁxed with 70% ethanol for an additional 16 h, after which the cells were stained with 500 ll of PI staining buffer. The cells were analyzed by ﬂow cytometry for
cell-cycle progression. Values are the mean ± S.E.M. of three independent experiments. ⁄P < 0.05.
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the GHS-R1a-expressing D0.11.10 T cells, cell-cycle analysis was
performed using propidium iodide (PI) staining of cells at 6 and
12 h post ghrelin stimulation. As shown in Fig. 7B, the PI-staining
demonstrated a lower proportion of cells in G1 phase (55.6%)
compared with the control cells (60.2%) at 12 h after ghrelin
treatment, while ghrelin-treated cells demonstrated a higher pro-
portion of cells in S phase compared to control cells at the 12 h
time period (Fig. 7B).
3.6. Ghrelin induces primary murine T cell proliferation
in a GHS-R1a-speciﬁc manner
To establish the physiological relevance of the signaling path-
ways through which ghrelin promotes the proliferation of GHS-
R1a- transfected D0.11.10 T cells, we next examined the ability
of acylated ghrelin and desacyl ghrelin (which cannot bindGHS-R1a), to promote the proliferation of T cells from C57BL/6
mice in concert with T-cell receptor crosslinking. T cells were trea-
ted with acylated ghrelin or desacyl ghrelin on plates coated with
anti-CD3 and CD28 monoclonal antibodies. T cell proliferation was
analyzed after 3 days of stimulation. Acylated ghrelin induced a
dose-dependent increase in anti-CD3/CD28-mediated CD4+ T cell
proliferation, whereas deacyl ghrelin failed to enhance T cell prolif-
eration (Fig. 8A). By contrast, both acylated ghrelin and desacyl
ghrelin failed to inﬂuence T cell proliferation when using GHS-R-
deﬁcient mouse CD4+ T cells (Fig. 8C). These data indicate that
the effect of ghrelin on CD4+ T cell proliferation speciﬁcally
depends on the GHS-R1a receptor.
Similarly to GHS-R1a- transfected D0.11.10 T cells, puriﬁed
murine CD4+ T cells treated with 100 nM of acylated ghrelin dem-
onstrated an increase in Akt, ERK1/2, PKC and PKCc phosphoryla-
tion starting at 5 min of ghrelin treatment (Fig. 8D). Many
attempts were made to examine the effects of ghrelin in
Fig. 8. Ghrelin stimulation of primary CD4+ T cells augments TCR-mediated proliferation and the phosphorylation of Akt or Erk1/2. (A, B) Puriﬁed murine CD4+ T cells were
isolated from C57BL/6 mice and treated with various concentrations of acylated ghrelin or desacyl ghrelin (100 nM) or in media alone on plates coated with anti-CD3 (1 lg/
ml) and CD28 (2 lg/ml) mAbs. The cells (1  105) were incubated for 3 days after which cell proliferation was examined using the MTS assay. (C) CD4+ T cells were isolated
from wild-type control mice and GHS-R knockout mice (GHS-R KO) and cultured in the presence or absence of acylated ghrelin (100 nM) or desacyl ghrelin (100 nM) on anti-
CD3/CD28 mAb-coated plates and were examined on days 1 and 3 for T cell proliferation. The data for panels A and B are expressed as % proliferation. ⁄P < 0.05, ⁄⁄P < 0.01
compared to PBS-treated mice. #P < 0.05, ##P < 0.01. values represent the mean and S.E.M. of determinations made in three independent experiments. (D) Puriﬁed murine
CD4+ T cells (5  106) were treated with acylated ghrelin (100 nM) for the speciﬁed time periods after which the cells were lysed and examined by immunoblot analysis for
phospho-Akt, ERK1/2, PKC and PKCc. Experiments were repeated 5 times and representative blots are shown. The numbers under each blot are the intensity of the indicated
band relative to that of the b-actin band.
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molecules. However, although some modest enhancement in
Erk1/2 signaling was noted in cells treated with both ghrelin and
anti-CD3/anti-CD28 (Supplemental Fig. 2), no effects were
observed on Akt activation. Thus, the contribution of ghrelin to
the TCR-mediated signaling process remains unclear. Additional
work is underway examining additional signaling pathways and
the role these may have in the anti-inﬂammatory and positive pro-
liferative/activation effects on CD4+ T cells.
Next, we examined the effects of ghrelin on thymocyte prolifer-
ation in vivo. Mice were injected i.p. with 100 lg/kg acylated ghre-
lin every 12 h for either 1 or 3 days. Control mice were injected
with the same volume of 0.9% saline. Two hours prior to euthana-
sia, all mice were injected i.p. with 100 mg/kg BrdU, and the thy-
mus was subsequently examined for the number of BrdU-
positive cells at day 1 and day 3 of ghrelin treatment. The results
in Fig. 9A reveal a signiﬁcant, albeit modest, increase in the num-
bers of BrdU-positive cells on day 3 in the ghrelin-treated group,
as compared to saline-treated mice, suggesting that ghrelin can
promote thymocyte proliferation in vivo. Only modest changes in
proliferating cells were observed at 24 h, with no effect on prolifer-
ation in sham control mice. Moreover, similarly to what was
observed with GHS-R1a- transfected D0.11.10 T cells and primary
CD4+ T cells, thymocytes derived from mice that had been treated
with 100 lg/kg acylated ghrelin every 12 h for 1 day demonstrated
an increase in cyclin D1 expression and in phosphorylation of Rb
(at S807/811, but not at S780Rb), Akt and ERK1/2 (Fig. 9B).
Finally, the effects of ghrelin on thymocyte proliferation were
investigated in middle-aged (12 month-old) and aged (22 month-
old) mice. Mice were treated with acylated ghrelin or with PBSfor 2 weeks using osmotic mini-pumps, and then thymocyte num-
bers were assessed. Aged and middle-aged mice demonstrated a
signiﬁcant increase in thymocyte cell numbers in response to acyl-
ated ghrelin infusion when compared to PBS sham control mice
(Supplemental Table 1). These ﬁndings support our previous obser-
vations [1,3,5] and suggest that ghrelin can be used as a therapeu-
tic tool for facilitating thymocyte restoration and proliferation in
aging and stressed animals.
4. Discussion
Our ﬁndings demonstrate that ghrelin exerts a direct effect on
the activation and proliferation of murine T cells in a PI3K- Akt-
and ERK1/2- dependent manner (Fig. 10). It was previously
reported that ghrelin can activate ERK1/2 via a Gq-dependent
pathway that involves PI3K/Akt [39]. The activation of this path-
way mediates the inhibitory effect of ghrelin on endothelial cell
apoptosis [39]. Similar ﬁndings have been obtained with cardio-
myocytes, neuronal cell populations, 3T3-L1 cells and several
tumor cell types [19,23,24,40,41].
Here, we show that ligation of acylated ghrelin to the GHSR-1a
receptor on T cells results in the activation of the kinases PI3K/Akt
and MAPK, which are known to play an important role in T cell
activation and proliferation. PLCb is activated through GHS-R1a
signaling via the activation of Gaq associated subunits resulting
in the phosphorylation of PI3K and Akt. Phosphorylation of Akt at
Thr-473/308 by PI3K results in increased activity of PKCc and PKCf.
The ghrelin-induced activation of Akt and Erk1/2 also results in the
induction of cyclin D1 and cyclin E1 expression and activation of
the downstream cyclin D1-associated kinases (CDKs), which play
Fig. 9. In vivo administration of ghrelin results in increased thymocyte proliferation and ghrelin receptor signaling in C57BL/6 mice. (A) C57BL/6 mice (11 weeks) were
injected with acylated ghrelin at 100 lg/kg and the thymuses were examined on day 3 using 5-bromo-20-deoxyridine (BrdU) staining. The number of BrdU-positive cells was
examined in the thymic sections from each animal (n = 5) and the data are expressed as BrdU-positive cells (±S.E.M.). ⁄⁄P < 0.01. (B) Thymocytes derived from two control and
two ghrelin-treated mice over a 24 h time period were examined for Erk1/2, Akt, Rb and cyclin D1 levels by immunoblot analysis.
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port a role for ghrelin signaling in T cell activation and proliferation
directly (as observed in D0.11.10 cells) or possibly via costimula-
tory pathways (as observed in primary CD4+ T cells). It should be
noted that although our cell culture experiments show that ghrelin
directly simulates T cell proliferation through the ghrelin receptor,
we cannot rule out the possibility that in vivo ghrelin impacts thy-
mocyte and T cell proliferation also indirectly, for example through
stimulation of growth hormone production.
The involvement of ERK, Akt and PI3K pathways in the prolifer-
ative response of T cells to ghrelin does not exclude the possible
involvement of a receptor type other than a G-protein-coupled
receptor. Recent ﬁndings suggest the existence of active acylated
ghrelin and desacyl-ghrelin binding sites on proteins other than
GHS-R1a [19,42]. For example, activation of ERK and PI3K/Akt
pathways was reported to be mediated not only by acylated ghre-
lin via GHS-R1a, but also by desacyl ghrelin via another unidenti-
ﬁed receptor, and this effect could not be blocked by the addition
of the GHS-R1a antagonist, (D-Lys3)-GHRP-6 [43]. In another
study, desacyl ghrelin was reported to activate Ca2+-activated K+
channels in mesenteric vascular endothelial cells via a GHS-R1a-
independent mechanism [42]. However, the latter ghrelin signaling
mechanism was not evident in T cells, as we observed no discern-
able effect of desacyl ghrelin on T cell proliferation.
Ghrelin differentially affects cell growth depending on the cell
type. Many endocrine and non-endocrine neoplastic cells have
been shown to express ghrelin and GHS-R1a, suggesting that this
hormone plays a role in the autocrine/paracrine regulation of
tumor growth and/or metastasis [44]. In thyroid and breast cell
lines, ghrelin inhibits serum-induced proliferation [45], while inother cell types, ghrelin stimulates cellular proliferation
[3,5,36,46]. Ghrelin stimulates proliferation of vascular endothelial
cells [24], pancreatic b-cells [25], cardiomyocytes [47], adipocytes
[41], adrenal cortical cells [48] and prostate cancer cells [45]. On
the other hand, ghrelin inhibits the proliferation of aortic smooth
muscle cells [49]and human umbilical vein endothelial cells [50].
Interestingly, whereas we found here that ghrelin enhanced the
proliferation of peripheral CD4+ murine T cells upon activation
with anti-CD3/CD28 mAb and thymic murine T cells upon in vivo
ghrelin administration, it has been reported that ghrelin can also
inhibit the proliferation of splenic T cells when they are stimulated
with anti-CD3 [51]. These differential effects of ghrelin on T cell
proliferation may depend upon the niche in which the T cells
reside, the state of immune cell activation and the activation stim-
uli used to promote cell proliferation. In addition to affecting T cell
proliferation, we recently demonstrated that ghrelin may act to
inhibit pro-inﬂammatory cytokine expression [27] and Th17 devel-
opment [28], possibly shifting T cell responses towards regulatory
phenotypes. The latter effects of ghrelin would be expected to sup-
press inﬂammation and, as our data suggest, may contribute to the
preservation of the thymic T cell population by ghrelin during
aging and in the presence of GCs.
Stimulation of proliferation of thymic T cells by ghrelin, via the
kinase cascades established in the present study, may contribute
to previously reported effects of fasting/dietary energy restriction
and stress responses on the thymus and T cells, as well as the
actions of ghrelin in maintaining thymus T cell numbers and
immune function during aging (Supplemental Table 1) [1,3,27].
Dietary energy restriction, which typically results in increased
levels of circulating acylated ghrelin, has been reported to
Fig. 10. GHS-R1a-mediated ghrelin signaling in murine CD4+ T cells. Ligation of acylated ghrelin to the GHS-R1a receptor results in the activation of the kinases PI3K/AKT and
MAPK, which play important roles in T cell activation and proliferation. PLCb is activated through GHS-R1a signaling via the activation of Gaq associated subunits resulting in
the phosphorylation of PI3K and AKT. Phosphorylation of AKT at Thr-473/308 by PI3K results in the activation of protein kinase activity. PLCb activates protein kinase C (PKC)
c and f and induces the phosphorylation of Erk1/2 resulting in the phosphorylation of cyclin D1 and E1, which play an important role in cell cycle progression. AKT also
regulate the Erk1/2 and the activation of cyclin D1 and E1 and the downstream cyclin D1 associated kinases (CDKs). Phosphorylation of Ser795 and Ser807/811in Rb is
thought to be mediated by the CDK4/6 and CDK2. Rb binds to the E2F-1 transcription factor preventing it from interacting with the cell’s transcription machinery. However,
upon phosphorylation, E2F mediates the transactivation of target genes that encode proteins that help to facilitate the G1/S transition and S-phase. Thus, ghrelin receptor
signaling inﬂuences T cell activation and promotes T cell proliferation directly (as observed with T-cell hybridoma cells) or possibly via costimulatory pathways (as observed
with primary CD4+ T cells). Ghrelin may counteract the adverse effects of chronic stress and aging on T cell proliferation and survival.
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can reduce age-related thymic involution in mice [53]. Caloric
restriction enhanced the responsiveness of splenic T cells to con-
canavalin A consistent with the ability of caloric restriction to
sustain immune function during aging [54]. Interestingly, similar
to ghrelin, caloric restriction inhibited the proliferation of splenic
T cells [55], while increasing the numbers of T cells in the thymus
[53]. A large-scale transcriptome analysis of the thymus in young,
middle-age and old mice that had been maintained on either a
usual diet or caloric restriction revealed that many age-related
changes in gene expression are attenuated or prevented by caloric
restriction [56]. Although the role of ghrelin in the latter effects of
caloric restriction on the aging thymus has not been established,
the elevation of ghrelin levels during caloric restriction suggests a
potential role for ghrelin and the signaling pathways identiﬁed in
the present study in preservation of T cells by caloric restriction.
Moreover, our ﬁndings that ghrelin treatment for 24 h also signif-
icantly restored the thymocyte loss induced by glucocorticoid
treatment (Fig. 1) suggests that ghrelin could be a potential ther-
apeutic tool for the treatment of conditions of physiological stress
that promote thymic involution, such as adrenal activation,
energy restriction, inﬂammation, chemotherapeutic ablation
[3,5]. A greater understanding of the interactions between meta-
bolic mediators and hormones with immune cell may revealnovel signaling pathways that inﬂuence immune function and
inﬂammation as well as deﬁne some of mechanisms by which
the various neuroendocrine and immune systems interact with
each other under conditions of disease, stress and aging.
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